Literature DB >> 23155142

Pulmonary vascular complications of liver disease.

Jason S Fritz1, Michael B Fallon, Steven M Kawut.   

Abstract

Hepatopulmonary syndrome and portopulmonary hypertension are two pulmonary vascular complications of liver disease. The pathophysiology underlying each disorder is distinct, but patients with either condition may be limited by dyspnea. A careful evaluation of concomitant symptoms, the physical examination, pulmonary function testing and arterial blood gas analysis, and echocardiographic, imaging, and hemodynamic studies is crucial to establishing (and distinguishing) these diagnoses. Our understanding of the pathobiology, natural history, and treatment of these disorders has advanced considerably over the past decade; however, the presence of either still increases the risk of morbidity and mortality in patients with underlying liver disease. There is no effective medical treatment for hepatopulmonary syndrome. Although liver transplantation can resolve hepatopulmonary syndrome, there appears to be worse survival even with transplantation. Liver transplantation poses a very high risk of death in those with significant portopulmonary hypertension, where targeted medical therapies may improve functional status and allow successful transplantation in a small number of select patients.

Entities:  

Mesh:

Year:  2012        PMID: 23155142      PMCID: PMC3570657          DOI: 10.1164/rccm.201209-1583CI

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  153 in total

1.  The hepatopulmonary syndrome: new name, old complexities.

Authors:  R Rodríguez-Roisin; A G Agustí; J Roca
Journal:  Thorax       Date:  1992-11       Impact factor: 9.139

2.  Multiple small arteriovenous fistulae of the lungs.

Authors:  M R HALES
Journal:  Am J Pathol       Date:  1956 Sep-Oct       Impact factor: 4.307

Review 3.  Endothelin and endothelin receptor antagonism in portopulmonary hypertension.

Authors:  W Neuhofer; V Gülberg; A L Gerbes
Journal:  Eur J Clin Invest       Date:  2006-09       Impact factor: 4.686

4.  Sildenafil citrate therapy for pulmonary arterial hypertension.

Authors:  Nazzareno Galiè; Hossein A Ghofrani; Adam Torbicki; Robyn J Barst; Lewis J Rubin; David Badesch; Thomas Fleming; Tamiza Parpia; Gary Burgess; Angelo Branzi; Friedrich Grimminger; Marcin Kurzyna; Gérald Simonneau
Journal:  N Engl J Med       Date:  2005-11-17       Impact factor: 91.245

5.  Haemodynamic adaptation two months after transjugular intrahepatic portosystemic shunt (TIPS) in cirrhotic patients.

Authors:  L A Colombato; L Spahr; J P Martinet; M P Dufresne; M Lafortune; D Fenyves; G Pomier-Layrargues
Journal:  Gut       Date:  1996-10       Impact factor: 23.059

6.  Hepatopulmonary syndrome versus portopulmonary hypertension: distinctions and dilemmas.

Authors:  M J Krowka
Journal:  Hepatology       Date:  1997-05       Impact factor: 17.425

7.  Pulmonary hypertension after liver transplantation in patients with antecedent hepatopulmonary syndrome: a report of 2 cases and review of the literature.

Authors:  Federico Aucejo; Charles Miller; David Vogt; Bijan Eghtesad; Shunichi Nakagawa; James K Stoller
Journal:  Liver Transpl       Date:  2006-08       Impact factor: 5.799

8.  Hepatopulmonary syndrome and portopulmonary hypertension: a report of the multicenter liver transplant database.

Authors:  Michael J Krowka; M Susan Mandell; Michael A E Ramsay; Steve M Kawut; Michael B Fallon; Cosme Manzarbeitia; Manuel Pardo; Paul Marotta; Shinji Uemoto; Markus P Stoffel; Joanne T Benson
Journal:  Liver Transpl       Date:  2004-02       Impact factor: 5.799

9.  Refractory hypoxemia during liver cirrhosis. Hepatopulmonary syndrome or "primary" pulmonary hypertension?

Authors:  O Raffy; C Sleiman; F Vachiery; H Mal; C Roue; A Hadengue; G Jebrak; M Fournier; R Pariente
Journal:  Am J Respir Crit Care Med       Date:  1996-03       Impact factor: 21.405

10.  Activity of the estrogen-metabolizing enzyme cytochrome P450 1B1 influences the development of pulmonary arterial hypertension.

Authors:  Kevin White; Anne Katrine Johansen; Margaret Nilsen; Loredana Ciuclan; Emma Wallace; Leigh Paton; Annabel Campbell; Ian Morecroft; Lynn Loughlin; John D McClure; Matthew Thomas; Kirsty M Mair; Margaret R MacLean
Journal:  Circulation       Date:  2012-08-02       Impact factor: 29.690

View more
  24 in total

Review 1.  The Art and Science of Diagnosing and Treating Lung and Heart Disease Secondary to Liver Disease.

Authors:  David S Goldberg; Michael B Fallon
Journal:  Clin Gastroenterol Hepatol       Date:  2015-04-28       Impact factor: 11.382

Review 2.  [Pulmonary complications in liver diseases].

Authors:  T Horvatits; A Drolz; K Rutter; S Kluge; V Fuhrmann
Journal:  Med Klin Intensivmed Notfmed       Date:  2014-04-26       Impact factor: 0.840

Review 3.  [Hepatocardiac disorders : Interactions between two organ systems].

Authors:  T Horvatits; A Drolz; K Rutter; K Roedl; S Kluge; V Fuhrmann
Journal:  Med Klin Intensivmed Notfmed       Date:  2015-06-13       Impact factor: 0.840

Review 4.  [Hepatopulmonary interactions].

Authors:  V Fuhrmann; P Tariparast
Journal:  Med Klin Intensivmed Notfmed       Date:  2018-08-06       Impact factor: 0.840

Review 5.  Sex, Gender, and Sex Hormones in Pulmonary Hypertension and Right Ventricular Failure.

Authors:  James Hester; Corey Ventetuolo; Tim Lahm
Journal:  Compr Physiol       Date:  2019-12-18       Impact factor: 9.090

6.  Portopulmonary hypertension: improved detection using CT and echocardiography in combination.

Authors:  Anand Devaraj; Robert Loveridge; Diana Bosanac; Konstantinos Stefanidis; William Bernal; Christopher Willars; Julia A Wendon; Georg Auzinger; Sujal R Desai
Journal:  Eur Radiol       Date:  2014-07-24       Impact factor: 5.315

Review 7.  Portopulmonary hypertension and hepatopulmonary syndrome.

Authors:  Florence Aldenkortt; Marc Aldenkortt; Laurence Caviezel; Jean Luc Waeber; Anne Weber; Eduardo Schiffer
Journal:  World J Gastroenterol       Date:  2014-07-07       Impact factor: 5.742

Review 8.  Treatment Barriers in Portopulmonary Hypertension.

Authors:  Batool AbuHalimeh; Michael J Krowka; Adriano R Tonelli
Journal:  Hepatology       Date:  2018-12-18       Impact factor: 17.425

9.  Impact of the hepatopulmonary syndrome MELD exception policy on outcomes of patients after liver transplantation: an analysis of the UNOS database.

Authors:  David S Goldberg; Karen Krok; Sachin Batra; James F Trotter; Steven M Kawut; Michael B Fallon
Journal:  Gastroenterology       Date:  2014-01-08       Impact factor: 22.682

Review 10.  Pulmonary complications of hepatic diseases.

Authors:  Salim R Surani; Yamely Mendez; Humayun Anjum; Joseph Varon
Journal:  World J Gastroenterol       Date:  2016-07-14       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.